Moving Towards Targeted Therapies for Triple-Negative Breast Cancer.
Moving Towards Targeted Therapies for Triple-Negative Breast Cancer.
复制标题
向三阴性乳腺癌的靶向治疗迈进。
DOI：
10.1007/s12609-021-00416-0
复制
发表时间：
2021-09
影响因子：
0.9
通讯作者：
Diamond JR
中科院分区：
文献类型：
--
作者：
Kagihara JA;Shagisultanova E;Afghahi A;Diamond JR
在这篇综述中，我们讨论了三阴性乳腺癌(TNBC)的感兴趣的靶点、批准的靶向药物以及导致它们批准的临床试验的结果。此外，我们回顾了正在进行的评估新型靶向药物在治疗TNBC中的使用的临床试验。TNBC占所有乳腺癌病例的15%-20%，并与较差的临床结果有关。与其他乳腺癌亚型相比，患者转移复发的风险更高，总体存活率更低。细胞毒性化疗历来是TNBC的主要治疗方法。近年来，我们看到研究靶向药物在TNBC中使用的临床试验激增，现在已经批准在特定患者中进行靶向治疗。PARP的抑制剂(olaparib和talazoparib)、PD-L1(Atezolizumab)和针对trop-2的抗体药物结合物(saituzumab gov.itecan-hziy)现已被批准用于选定的TNBC患者组。目前正在研究各种新型靶向药物，如单一疗法、双靶向联合疗法和化疗联合疗法。结果是有希望的，可能会显著改善TNBC患者的预后。
In this review, we discuss targets of interest in Triple-negative breast cancer (TNBC), approved targeted agents and the results of the clinical trials that led to their approval. Additionally, we review ongoing clinical trials evaluating the use of novel targeted agents in the treatment of TNBC. TNBC accounts for 15–20% of all breast cancer cases and is associated with worse clinical outcomes. Patients have a higher risk of metastatic recurrence and inferior overall survival compared to other breast cancer subtypes. Cytotoxic chemotherapy has historically been the mainstay of treatment for TNBC. In recent years, we have seen a surge in clinical trials investigating the use of targeted agents in TNBC and now have approval for targeted therapies in select patients. Inhibitors of PARP (olaparib and talazoparib), PD-L1 (atezolizumab) and an antibody drug conjugate targeting Trop-2 (sacituzumab govitecan-hziy) are now approved for the use in select groups of patients with TNBC. Various novel targeted agents as monotherapy, dual targeted combinations, and chemotherapy combinations are currently under investigation. The results are promising and may significantly improve patient outcomes in TNBC.
登录
查看更多内容
三重阴性乳腺癌中肿瘤浸润的淋巴细胞：免疫靶向的未来。
DOI：
10.4137/cmo.s34540
发表时间：
2016
期刊：
Clinical Medicine Insights. Oncology
影响因子：
--
作者：
García-Teijido P;Cabal ML;Fernández IP;Pérez YF
通讯作者：
Pérez YF
影响因子：
30.8
作者：
Gao, Ruli;Davis, Alexander;McDonald, Thomas O.;Sei, Emi;Shi, Xiuqing;Wang, Yong;Tsai, Pei-Ching;Casasent, Anna;Waters, Jill;Zhang, Hong;Meric-Bernstam, Funda;Michor, Franziska;Navin, Nicholas E.
通讯作者：
Navin, Nicholas E.
影响因子：
8
作者：
Doane, A. S.;Danso, M.;Gerald, W. L.
通讯作者：
Gerald, W. L.
影响因子：
8.4
作者：
Gobbini, Elisa;Ezzalfani, Monia;Delaloge, Suzette
通讯作者：
Delaloge, Suzette
影响因子：
2.6
作者：
Ismail-Khan, Roohi;Bui, Marilyn M.
通讯作者：
Bui, Marilyn M.